CN106421917A - Method for preparing composition for repairing cartilage injuries - Google Patents
Method for preparing composition for repairing cartilage injuries Download PDFInfo
- Publication number
- CN106421917A CN106421917A CN201610980000.1A CN201610980000A CN106421917A CN 106421917 A CN106421917 A CN 106421917A CN 201610980000 A CN201610980000 A CN 201610980000A CN 106421917 A CN106421917 A CN 106421917A
- Authority
- CN
- China
- Prior art keywords
- cell
- cartilage
- composition
- cell suspension
- mescenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a method for preparing a composition for repairing cartilage injuries. The method comprises the following steps: (1) mixing mesenchymal stem cells with chondrocytes, and re-suspending in a hyaluronic acid solution to obtain a cell suspension; and (2) mixing the cell suspension with a thermosensitive hydrogel to obtain the composition for repairing cartilage injuries. The method is convenient to operate and easy to implement; the obtained composition for repairing cartilage injuries is safe and reliable, is efficient to be differentiated into the chondrocytes, and can provide the cells necessary to tissue repair for cartilage injury sites; and the thermosensitive hydrogel plays a role of exogenous cell carrier, can make the cells in the composition fully fill the cartilage injury sites and not migrate to other parts, thereby effectively promoting the cartilage injury sites to be quickly and effectively repaired and healed.
Description
Technical field
The present invention relates to the method preparing the composition repaired for cartilage damage.
Background technology
It is that osteoarthritis (osteoarthritis, OA) occurs that articular cartilage (articular cartilage, AC) is damaged
Major Risk Factors, OA is irreversible, to be palliated the agonizing sufferings by joint replacement when PD is to late period and
Recover function.Because the repair ability of articular cartilage is limited it is necessary to early intervention is to prevent from developing into OA.Current controls
Treatment mode is intended to stimulate by primary treatment, adjacent tissue and transplanting carrys out repairing articular cartilage.Can by rational repairing and treating
To obtain comparatively ideal result in short-term to mid-term, but after longer period of time, easily recur.In recent years, based on bioengineering
The tissue engineering technique of the cellular level of tissue is widely studied, and this bioengineered tissue can reappear hyaline cartilage
Characteristic, and combine together with original tissue, repairing articular cartilage is damaged significant.
However, current bioengineered tissue repair cartilage damage aspect research still have to be strengthened.
Content of the invention
It is contemplated that at least solving one of technical problem present in prior art.For this reason, one object of the present invention
Be to propose a kind of convenient obtain, safe and reliable, can effectively repair the means of cartilage damage.
It should be noted that the present invention is to be completed based on the following discovery of inventor：
One of wide cartilage repair techniques of cellular level of application are Autologous Chondrocyte transplanting at present
(Autologous chondrocyte implantation, ACI) technology.This technology comprises internal operative treatment and thin in vitro
Born of the same parents' culture technique：First, the non-bearing region in damaged joints carries out operation acquisition cartilage slices, and is transferred into storing
And in the sterile nutrient solution of transport；Then, using collagenase digesting cartilaginous tissue in cell culture chamber, obtain cartilage cell,
Using monolayer cultivation, cultured chondrocytes are expanded to the quantity that can be used for transplanting, filling out of cartilage defects is carried out by surgeon
Fill.In this surgical procedure, the cartilage cell of amplification in vitro is expelled to fault location.In order that cartilage cell rests on transplanting portion
Position, prevents from floating in a large number, further synovial membrane lobe can be sewn to damage location.However, it is found by the inventors that, Autologous Chondrocyte
There is following defect in transplanting：1st, Autologous Chondrocyte transplanting needs Two intrusions to perform the operation, larger to damage to patient.2nd, cartilage is thin
In vitro during individual layer amplification, these cell masses lose its phenotype to born of the same parents, and the production of collagen is (typically transparent by II type
Cartilage) to I type and type III (typical fibrocartilage) transformation.The result of the change of these phenotypes is that have poor biology
The generation of the extracellular matrix of mechanical performance.3rd, the substantial amounts of cartilage cell's of donor site offer is limited in one's ability.4th, donor set
The incidence of disease be also Autologous Chondrocyte major obstacle.
And autologous bone marrow mesenchymal stem cells transplanting is also the cartilage repair techniques of the wide cellular level of current application.
This technology carries out bone marrow aspiration in the ilium of patient, collects marrow；Sample is transferred to toilet and carries out cell separation；To marrow
Add phosphate buffer in puncture fluid, be then transferred in lymphocyte separation medium, be centrifuged and collect mononuclearcell and count
Number, is washed with PBS, is then seeded to culture in blake bottle, so that by gained cell amplification cultivation, passes to the second generation and prepares to move
Plant；Before transplanting using colony forming unit (Colony-forming unit, CFU) and Flow cytometry cell gram
Grand Forming ability and the expression of cell surface marker；Then, the MSCs pancreatin of the second generation is digested, and be resuspended in life
During regulating blood condition is clear, and it is loaded in asepsis injector, under perspective, at cell infusion to the knee injuries of patient.However, inventor
Find, autologous bone marrow mesenchymal stem cells transplanting has following defect：1st, bone marrow aspiration brings misery to patient.2nd, cell is direct
It is expelled to injury region, does not do other measures, cell may float in a large number.3rd, brachymedial phase effect is preferable, but long-time after
The injury region pain of patient has risen, and ability to act has also declined.
And mescenchymal stem cell (mesenchymal stem cells, MSCs) transplanting is the very promising strategy of one kind,
Because MSCs has high proliferation ability and has the potential being divided into cartilage cell, and then form cartilage.MSCs is that fusiformis is thin
Born of the same parents, have fast breeding and self-renewal capacity, are present in a large amount of tissues, including marrow, synovial tissue, blood, fatty group
Knit and periosteal tissue.They have polyphyly differentiation potential, can be divided into various kinds of cell type to create and to repair mesenchyma group
Knit.MSCs can be to one-tenth cartilage, skeletonization, fatty development ways differentiation.Regulatory factor can promote the cartilage of MSC to occur, for example
TGF (TGF-β) and dexamethasone, this is confirmed with simple external model.
And then, inventor passes through a series of researchs and finds, using the mescenchymal stem cell (Umbilical in umbilical cord source
Cord Mesenchymal stem cells, UCMSC) it is transplanted at the injury of knee joint of patient, can damage effectively treatment cartilage
Wound.And, existing ripe UCMSC isolated culture method, and umbilical cord at present easily obtains it is not necessary to take invasive to patient
Operation, it is not required that extracting cartilage in other positions, can effectively reduce the misery of patient.And MSC can fast breeding and from
I updates, and has into the potential of cartilage differentiation, ensure that the vigor of neocartilage cell, and there is not the hidden of the incidence of disease
Suffer from.
Further, inventor before transplantation, carries out into chondrocyte induction differentiation, to promote UCMSC to cartilage to part UCMSC
Direction breaks up, and the cartilage cell of UCMSC and induction is combined with hyaluronic acid (HA) and temperature-sensitive hydrogel, and result can
Effectively prevent cell extensive migration, reach the effect of long-term treatment.Wherein, temperature sensitive type poly lactic acid hydrogel is below 37 DEG C
Liquid, will form gel after reaching 37 DEG C, play a part exogenous cells carrier, can promote cell movement, stick,
Propagation and differentiation, and provide structural support so that cell activity at defect, will not large area move.
Thus, in one aspect of the invention, the invention provides a kind of prepare the composition repaired for cartilage damage
Method.According to embodiments of the invention, the method includes：(1) mescenchymal stem cell and cartilage cell are mixed and be resuspended in
In hyaluronic acid solution, to obtain cell suspension；And described cell suspension is mixed by (2) with temperature-sensitive hydrogel,
To obtain the described composition repaired for cartilage damage.
It is surprisingly found by the inventors that, the method is easy to operate, easy to implement, the combination repaired for cartilage damage of acquisition
Thing is safe and reliable, to the efficiency high of Chondrocyte Differentiation, can provide cell necessary to tissue repair for cartilaginous lesion site,
And temperature-sensitive hydrogel has the effect of good exogenous cells carrier, the cell in composition can be made to be sufficient filling with cartilage
Injury region and quickly and efficiently repair and heal such that it is able to effectively facilitate cartilaginous lesion site not to other local migrations.
According to embodiments of the invention, in described cell suspension, described mescenchymal stem cell and described cartilage cell's
Mixed proportion is 1:1～4:1.Thus, the composition for cartilage damage reparation preparing is to the effect of Chondrocyte Differentiation
Rate is high, can provide cell necessary to tissue repair for cartilaginous lesion site.
According to embodiments of the invention, in described cell suspension, the content of hyaluronic acid is 5～30mg/ml.Thus,
In the composition repaired for cartilage damage preparing, the answering of cell mixture and hyaluronic acid and temperature-sensitive hydrogel
Close effect good, can effectively prevent cell extensive migration, such that it is able to reach the effect of long-term treatment.
According to embodiments of the invention, the volume ratio of described cell suspension and described temperature-sensitive hydrogel is 1:1～2.By
This, in the composition repaired for cartilage damage preparing, temperature-sensitive hydrogel is done thin to the mesenchyma in cell suspension
The supporting effect of born of the same parents and cartilage cell's mixture is good, and then the cell in composition can be made to be sufficient filling with cartilage damage and not
Quickly and efficiently repair and heal such that it is able to effectively facilitate cartilaginous lesion site to other local migrations.
According to embodiments of the invention, described temperature-sensitive hydrogel is temperature sensitive type poly lactic acid hydrogel.Thereby, it is possible to effective
Carry mescenchymal stem cell and cartilage cell's mixture, and so that it is sufficient filling with cartilage damage and not to other local migrations.
According to embodiments of the invention, described temperature sensitive type poly lactic acid hydrogel is MPEG-PLGA.Thus, it is as external source
Property the making good use of of cell carrier, the cell in the composition of acquisition can be made to be sufficient filling with cartilage damage and to other local
Migration is quickly and efficiently repaired and is healed such that it is able to effectively facilitate cartilaginous lesion site.
According to embodiments of the invention, described mescenchymal stem cell is umbilical cord mesenchymal stem cells.Thus, mesenchyma is done carefully
Born of the same parents' wide material sources, easily obtain, safe and harmless, and the efficiency high to cartilage differentiation.
According to embodiments of the invention, described cartilage cell is by the preferred umbilical cord mesenchymal stem cells of mescenchymal stem cell
Induction obtains.And, the abductive approach of cartilage cell is not particularly limited, as long as can be from the preferred umbilical cord of mescenchymal stem cell
Mescenchymal stem cell effectively induces acquisition cartilage cell.Thus, the composition repaired for cartilage damage of acquisition, to soft
The efficiency high of bone cell differentiation, can provide cell necessary to tissue repair for cartilaginous lesion site.
In addition it is also necessary to illustrate, the present invention has at least one of following advantages：
1st, the inventive method, obtains mescenchymal stem cell, wide material sources by discarded object umbilical cord, can obtain in a large number, and will not
Patient is damaged.
2nd, the present invention carries out the induction differentiation in cartilage cell direction to part UCMSC, promotes UCMSC to cartilage differentiation
Efficiency.
3rd, temperature-sensitive hydrogel can play the effect of good exogenous cells carrier so that cell can be sufficient filling with
At cartilage damage, and not to other local migrations.
The additional aspect of the present invention and advantage will be set forth in part in the description, and partly will become from the following description
Obtain substantially, or recognized by the practice of the present invention.
Specific embodiment
Below in conjunction with embodiment, the solution of the present invention is explained.It will be understood to those of skill in the art that it is following
Embodiment is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.Unreceipted particular technique or bar in embodiment
Part, carry out according to the technology described by document in the art or condition or according to product description.Agents useful for same or instrument
The unreceipted production firm person of device, be can by city available from conventional products.
Embodiment 1
With reference to the method for the present invention, prepare, according to following steps, the composition repaired for cartilage damage, and cartilage is damaged
Sick and wounded people carries out skin grafing and mending：
1st, being separately cultured of UCMSC
The fresh umbilical cord got is sent into GMP workshop, separates and obtain UCMSC.UCMSC is cultivated amplification；And take out
Part cell carries out chondroblast induction, expands, prepare transplanting after obtaining a number of cartilage cell.
2nd, prepare before transplanting
The cartilage cell that UCMSC obtained above is obtained with induction differentiation, is digested with 0.25% pancreatin, is used in combination
Brine, then by UCMSC and cartilage cell according to 1:1～4:1 ratio mixes and is resuspended in hyaluronic acid solution
In, to obtain cell suspension, wherein in cell suspension, the content of hyaluronic acid is 5～30mg/ml.By this cell suspension and temperature
Quick type PLA hydrogel MPEG-PLGA is mixed with 1: 1～2 volume ratio, and being placed in shaking table makes it fully mix for a period of time, with
Just obtain the composition repaired for cartilage damage of the present invention.
Then, for the cell sampling in the composition of cartilage damage reparation, microorganism, virus five are carried out to the present invention
Item, mycoplasma, endotoxin and cell function detection, to guarantee security.
3rd, transplant
Using joint cavity injection method.Wherein, patient carries out arthroscopy before accepting injection, determines at joint injury
Size, thickness etc., with every square centimeter 5 × 106The density of cell is injected.
4th, effect observation after transplanting
After treatment, periodically adopt the improvement situation of nuclear magnetic resonance image check knee joint function.
It was found that the cell in the composition for cartilage damage reparation of the present invention can be sufficient filling with cartilage damage
Place and not to other local migrations, cartilaginous lesion site healing is quick, effectively.
Comparative example 1
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
Chondrocyte induction is not carried out to UCMSC, that is, the cell in cell suspension is all using UCMSC.
Observe after transplanting, patient's cartilaginous lesion site chondroid tissue, Principle of Pain is alleviated, damage to have and to a certain degree heal
Close.
Comparative example 2
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
The ratio of the UCMSC in cell suspension and cartilage cell is 1：3.
Observe after transplanting, patient's cartilaginous lesion site healing speed is slow.
Comparative example 3
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
The ratio of cell suspension and temperature sensitive type poly lactic acid hydrogel MPEG-PLGA is 1: 3.
Observe after transplanting, patient's cartilaginous lesion site cartilage cell's formation efficiency is relatively low, thus healing speed is slow.
Comparative example 4
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
The ratio of cell suspension and temperature sensitive type poly lactic acid hydrogel MPEG-PLGA is 1：3.
Observe after transplanting, patient's cartilaginous lesion site cartilage cell's formation efficiency is relatively low, and healing speed is slow.
Comparative example 5
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
Do not adopt temperature sensitive type poly lactic acid hydrogel MPEG-PLGA (carrying out injection transplantation only with cell suspension).
Observe after transplanting, a large amount of drift of the cell in composition is walked, patient's cartilaginous lesion site cartilage cell's formation efficiency
Relatively low, healing speed is slow.
Comparative example 6
Method according to embodiment 1 prepares the composition repaired for cartilage damage, and cartilage damage patient is moved
Plant and repair, differ only in：
Hyaluronic acid solution is substituted using physiological saline.
Observe after transplanting, a large amount of drift of the cell in composition is walked, patient's cartilaginous lesion site cartilage cell's formation efficiency
Relatively low, healing speed is slow.
In the description of this specification, reference term " embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or the spy describing with reference to this embodiment or example
Point is contained at least one embodiment or the example of the present invention.In this manual, to the schematic representation of above-mentioned term not
Necessarily refer to identical embodiment or example.And, the specific features of description, structure, material or feature can be any
One or more embodiments or example in combine in an appropriate manner.
Although an embodiment of the present invention has been shown and described, it will be understood by those skilled in the art that：Not
Multiple changes, modification, replacement and modification can be carried out to these embodiments in the case of the principle of the disengaging present invention and objective, this
The scope of invention is limited by claim and its equivalent.
Claims (8)
1. a kind of method preparing the composition repaired for cartilage damage is it is characterised in that include：
(1) mescenchymal stem cell and cartilage cell are mixed and be resuspended in hyaluronic acid solution, to obtain cell suspension；With
And
(2) described cell suspension is mixed with temperature-sensitive hydrogel, to obtain the described group repaired for cartilage damage
Compound.
2. method according to claim 1 is it is characterised in that in described cell suspension, described mescenchymal stem cell and
The mixed proportion of described cartilage cell is 1:1～4:1.
3. method according to claim 1 is it is characterised in that in described cell suspension, and the content of hyaluronic acid is 5～
30mg/ml.
4. method according to claim 1 is it is characterised in that the volume of described cell suspension and described temperature-sensitive hydrogel
Than for 1:1～2.
5. method according to claim 1 is it is characterised in that described temperature-sensitive hydrogel is temperature sensitive type poly lactic acid water-setting
Glue.
6. method according to claim 4 is it is characterised in that described temperature sensitive type poly lactic acid hydrogel is MPEG-PLGA.
7. method according to claim 1 is it is characterised in that described mescenchymal stem cell is umbilical cord mesenchymal stem cells.
8. method according to claim 1 is it is characterised in that described cartilage cell is by the preferred navel of mescenchymal stem cell
Obtain with mescenchymal stem cell induction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980000.1A CN106421917A (en) | 2016-11-08 | 2016-11-08 | Method for preparing composition for repairing cartilage injuries |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980000.1A CN106421917A (en) | 2016-11-08 | 2016-11-08 | Method for preparing composition for repairing cartilage injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106421917A true CN106421917A (en) | 2017-02-22 |
Family
ID=58207789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610980000.1A Pending CN106421917A (en) | 2016-11-08 | 2016-11-08 | Method for preparing composition for repairing cartilage injuries |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421917A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822876A (en) * | 2017-02-27 | 2017-06-13 | 山东景源生物科技有限公司 | A kind of medicine for blocking gonitis articular cartilage damage patient's inflammatory factor |
| CN108743618A (en) * | 2018-04-25 | 2018-11-06 | 中国人民解放军***总医院 | A kind of preparation method and applications of syringeability stem cell aqueogel |
| CN110302430A (en) * | 2019-07-03 | 2019-10-08 | 上海交通大学医学院附属第九人民医院 | Biological 3D printing implanted gel and its application in facial soft tissue defect repair |
| CN110662563A (en) * | 2017-03-31 | 2020-01-07 | 迪帕克.简 | Injectable cell and scaffold compositions |
| CN112336751A (en) * | 2020-11-27 | 2021-02-09 | 福建华民生物科技有限公司 | Medicine for treating cartilage injury and arthritis and matched injection device thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101291586A (en) * | 2005-09-02 | 2008-10-22 | 英特菲思生物技术公司 | A method for cell implantation |
| CN101934092A (en) * | 2010-08-27 | 2011-01-05 | 中国人民解放军第三军医大学第一附属医院 | Injection-type cartilage bionic matrix for regenerative repair of cartilage and method for using same |
| CN102123745A (en) * | 2008-02-29 | 2011-07-13 | 科洛普拉斯特公司 | Compositions and methods for augmentation and regeneration of living tissue in a subject |
| CN102488925A (en) * | 2011-12-29 | 2012-06-13 | 成都普川生物医用材料股份有限公司 | Injectable articular cartilage tissue repair material and its preparation method |
| CN104436306A (en) * | 2014-11-11 | 2015-03-25 | 四川大学 | Cell-gel material composite microsphere as well as preparation method and application thereof |
| CN104962517A (en) * | 2015-07-29 | 2015-10-07 | 西安芙金细胞科技有限公司 | Preparation, induced differentiation and application of self-assembled mesenchymal stem cell aggregate |
| CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
| CN107550935A (en) * | 2017-09-11 | 2018-01-09 | 上海亚睿生物科技有限公司 | A kind of biological gel for treating joint disease and its application |
-
2016
- 2016-11-08 CN CN201610980000.1A patent/CN106421917A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101291586A (en) * | 2005-09-02 | 2008-10-22 | 英特菲思生物技术公司 | A method for cell implantation |
| CN102123745A (en) * | 2008-02-29 | 2011-07-13 | 科洛普拉斯特公司 | Compositions and methods for augmentation and regeneration of living tissue in a subject |
| CN101934092A (en) * | 2010-08-27 | 2011-01-05 | 中国人民解放军第三军医大学第一附属医院 | Injection-type cartilage bionic matrix for regenerative repair of cartilage and method for using same |
| CN102488925A (en) * | 2011-12-29 | 2012-06-13 | 成都普川生物医用材料股份有限公司 | Injectable articular cartilage tissue repair material and its preparation method |
| CN104436306A (en) * | 2014-11-11 | 2015-03-25 | 四川大学 | Cell-gel material composite microsphere as well as preparation method and application thereof |
| CN104962517A (en) * | 2015-07-29 | 2015-10-07 | 西安芙金细胞科技有限公司 | Preparation, induced differentiation and application of self-assembled mesenchymal stem cell aggregate |
| CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
| CN107550935A (en) * | 2017-09-11 | 2018-01-09 | 上海亚睿生物科技有限公司 | A kind of biological gel for treating joint disease and its application |
Non-Patent Citations (1)
| Title |
|---|
| 符旭东等: ""硫酸长春碱温敏性凝胶的释药特性和抗血管生成活性研究"", 《中国药学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822876A (en) * | 2017-02-27 | 2017-06-13 | 山东景源生物科技有限公司 | A kind of medicine for blocking gonitis articular cartilage damage patient's inflammatory factor |
| CN110662563A (en) * | 2017-03-31 | 2020-01-07 | 迪帕克.简 | Injectable cell and scaffold compositions |
| CN108743618A (en) * | 2018-04-25 | 2018-11-06 | 中国人民解放军***总医院 | A kind of preparation method and applications of syringeability stem cell aqueogel |
| CN110302430A (en) * | 2019-07-03 | 2019-10-08 | 上海交通大学医学院附属第九人民医院 | Biological 3D printing implanted gel and its application in facial soft tissue defect repair |
| CN110302430B (en) * | 2019-07-03 | 2021-06-29 | 上海交通大学医学院附属第九人民医院 | Biological 3D printing implantation gel and application thereof in soft tissue defect repair |
| CN112336751A (en) * | 2020-11-27 | 2021-02-09 | 福建华民生物科技有限公司 | Medicine for treating cartilage injury and arthritis and matched injection device thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Clinical application status of articular cartilage regeneration techniques: tissue‐engineered cartilage brings new hope | |
| Yin et al. | Induction of mesenchymal stem cell chondrogenic differentiation and functional cartilage microtissue formation for in vivo cartilage regeneration by cartilage extracellular matrix-derived particles | |
| JP5928961B2 (en) | Application of synovial mesenchymal stem cells (MSCs) to cartilage and meniscal regeneration | |
| Wang et al. | Cartilage regeneration in SCID mice using a highly organized three-dimensional alginate scaffold | |
| CN102188748B (en) | Novel chondrocyte epimatrix membrane and preparation method thereof | |
| Li et al. | 3D-printed scaffolds with calcified layer for osteochondral tissue engineering | |
| CN106421917A (en) | Method for preparing composition for repairing cartilage injuries | |
| DK2307065T3 (en) | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGULATION | |
| Chiang et al. | Repair of porcine articular cartilage defect with autologous chondrocyte transplantation | |
| CN102716515B (en) | Biological material for repairing meniscus tear and preparation method for biological material | |
| KR101836475B1 (en) | Composition for cartilage regeneration and preparing thereof | |
| JP2005501101A (en) | Composition for treating articular cartilage injury | |
| CN107223153A (en) | Efflux body comprising the stem cell for coming from positive differentiating cartilage-forming cell be used for Chondrocyte Differentiation induce or regenerative agent of cartilaginous tissue composition | |
| CN111849882A (en) | Mesenchymal stem cell exosome and preparation method and application thereof | |
| Oshima et al. | A scaffold-free allogeneic construct from adipose-derived stem cells regenerates an osteochondral defect in a rabbit model | |
| CN108865986B (en) | Mesenchymal stem cell preparation for repairing articular cartilage damage/defect and preparation method and application thereof | |
| CN106474156A (en) | Purposes in preparing medicine for the compositionss | |
| CN107376025B (en) | Preparation method and application of cell-scaffold composite material for cartilage injury repair | |
| Özdemir et al. | Biological augmentation strategies in rotator cuff repair | |
| CN108096632B (en) | Articular cartilage repair materials and preparation method based on oxidized hyaluronic acid-II Collagen Type VI and self concentration bone marrow nucleated cell | |
| CN106421918A (en) | Chondrocyte composition | |
| CN106552288A (en) | The method for preparing chondrocyte composition | |
| CN111514374A (en) | Method for promoting cartilage repair by using tissue engineering cartilage constructed based on co-culture system | |
| CN111407785A (en) | Composite acellular matrix injection for treating femoral head necrosis and using method | |
| Li et al. | Early efficacy of type I collagen-based matrix-assisted autologous chondrocyte transplantation for the treatment of articular cartilage lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |